EGFR and lung carcinoma: In the next section, we will review the current literature for previous generation and newly developed compounds that are able to target EGFR Ex20ins and discuss the advantages and disadvantages for the use of these targeted therapies in the treatment of SNSCCs based on the extensive clinical experience gained in the context of lung cancer.